Alex Rodriguez TRT: How His Protocol Compares to Non-Celebrity Outcomes

The Rodriguez Doping Record: What the Documents Actually Show

Alex Rodriguez admitted in 2009 to using testosterone and an unspecified "banned substance" between 2001 and 2003, when he tested positive during MLB's anonymous survey. The specific compound reported was testosterone alongside Primobolan (methenolone), an anabolic steroid favored for lean-mass retention with relatively low androgenic conversion. Ten years later, the Biogenesis of America investigation produced far more granular records.

The 2003 Positive Test

The 2003 survey was intended to measure the prevalence of steroid use across the league, not to penalize players. Rodriguez's sample reportedly showed exogenous testosterone at supraphysiologic levels. Primobolan, an injectable or oral 17-beta-esterified anabolic steroid, does not convert to estrogen and is therefore preferred by athletes who want to avoid gynecomastia while maintaining muscle during caloric restriction. The compound is not approved by the FDA for any use in the United States and carries no legitimate prescription pathway for performance enhancement. fda.gov

The Biogenesis Dossier (2010 to 2012)

Biogenesis of America, a now-shuttered anti-aging clinic in Coral Gables, Florida, supplied multiple MLB players with performance-enhancing compounds. According to documents obtained by MLB investigators and later reported by the Miami New Times, Rodriguez received testosterone cream, human growth hormone (HGH), insulin-like growth factor-1 (IGF-1), and peptides including what was described as a "pink cream" applied transdermally. These are not the compounds or doses any current clinical guideline recommends for hypogonadism management.

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism explicitly states that testosterone therapy is indicated only when serum total testosterone is below 300 ng/dL on two morning measurements, confirmed with validated assays. [1] Rodriguez has never disclosed a diagnosis of hypogonadism. His use therefore falls outside every established clinical framework for therapeutic testosterone.

Standard TRT Protocols: What Non-Celebrity Patients Actually Receive

Clinical TRT looks almost nothing like what Biogenesis supplied. Understanding that contrast is the core clinical value of examining this case.

Approved Formulations and Doses

The FDA has approved several testosterone formulations for male hypogonadism. Testosterone cypionate and enanthate, both intramuscular injectables, are the most commonly prescribed. Standard dosing is 100 to 200 mg IM every 7 to 14 days, titrated to maintain total testosterone between 400 and 700 ng/dL. [2] Testosterone undecanoate (Aveed) is dosed at 750 mg IM at 0, 4, and then every 10 weeks. Topical gels (AndroGel 1.62%, Testim) deliver 40.5 to 81 mg of testosterone daily. Pellets (Testopel) release testosterone subcutaneously over 3 to 6 months.

None of these protocols involve IGF-1 injections, HGH co-administration, or peptide stacks. Adding HGH to a TRT regimen is not standard of care for any FDA-approved indication in otherwise healthy men. [3]

Monitoring Requirements

The Endocrine Society guideline recommends checking hematocrit at baseline and at 3 and 6 months, then annually, because supraphysiologic testosterone stimulates erythropoiesis. A hematocrit above 54% is a stopping criterion. [1] Clinicians also monitor total testosterone, free testosterone, estradiol, PSA (in men over 40), and lipid panels. The monitoring cadence Rodriguez would have needed, if treated clinically, was quarterly for the first year.

Biogenesis Compounds vs. Guideline TRT: A Side-by-Side Comparison

The table below maps reported Biogenesis substances to their clinical equivalents (or lack thereof), their mechanism, and their regulatory status.

| Substance (Biogenesis) | Clinical Equivalent | Mechanism | FDA Status | |---|---|---|---| | Testosterone cream (transdermal) | AndroGel / Testim | Androgen receptor agonist | Approved for hypogonadism | | Primobolan (methenolone) | None | Anabolic steroid, low aromatization | Not FDA-approved (any use) | | Human Growth Hormone (HGH) | Somatropin | GH receptor agonist | Approved for adult GHD, not athletic use | | IGF-1 (mecasermin) | Increlex (mecasermin) | IGF-1R agonist | Approved for severe primary IGF-1 deficiency in children only | | Unspecified peptides | None confirmed | Variable | Not FDA-approved for PED use |

An everyday TRT patient prescribed testosterone cypionate by a telehealth or in-person endocrinologist receives exactly one compound from that list, at doses calculated to restore, not exceed, the physiologic range.

What Outcomes Do Non-Celebrity TRT Patients Actually Achieve?

This question matters most for men reading about Rodriguez and wondering whether testosterone therapy offers them anything real.

Lean Mass and Body Composition

A 2013 meta-analysis by Ottenbacher et al. Published in the Journal of the American Geriatrics Society (N=1,083 men across 22 trials) found that testosterone therapy increased lean body mass by a mean of 1.6 kg and reduced fat mass by 1.2 kg compared to placebo over 12 weeks. [4] These are modest but statistically significant (P<0.001) changes. Rodriguez, using supraphysiologic testosterone alongside IGF-1 and HGH during his peak playing years, was operating in an entirely different pharmacologic regime. Any comparison flatters neither side: one is medically supervised restoration, the other is performance enhancement well above the physiologic ceiling.

Sexual Function and Mood

The TRAVERSE trial (N=5,204), the largest randomized controlled trial of testosterone therapy in men with hypogonadism and established or high risk of cardiovascular disease, found statistically significant improvements in sexual activity, desire, and erectile function versus placebo at 24 months. [5] Mood improvements, including reductions in depressive symptoms measured by PHQ-9, were also significant. These are the realistic benefits a non-celebrity 45-year-old man with confirmed hypogonadism can expect from guideline-concordant TRT.

Cardiovascular Safety

The TRAVERSE trial also provided the most definitive cardiovascular safety data to date. The rate of major adverse cardiovascular events (MACE) was 7.0% in the testosterone group versus 7.3% in placebo (hazard ratio 0.96, 95% CI 0.83 to 1.12), meeting the non-inferiority threshold. [5] This resolved years of regulatory uncertainty after the FDA required a cardiovascular outcomes trial following the 2010 Basaria et al. TOM trial, which was stopped early due to increased cardiovascular events in frail older men. [6]

Bone Density

The Testosterone Trials (TTrials, N=788, seven coordinated trials) found that testosterone therapy increased volumetric bone mineral density at the lumbar spine by 7.5% and trabecular bone score by 1.9% after 12 months in men with low testosterone. [7] For men with established osteopenia or fracture risk, this is a clinically meaningful endpoint. Supraphysiologic doping regimens, by contrast, can suppress the HPG axis and reduce endogenous testosterone production for months to years after cessation.

The HPG Axis Disruption: The Part Celebrities Do Not Talk About

Exogenous testosterone, regardless of source, suppresses the hypothalamic-pituitary-gonadal (HPG) axis through negative feedback. Within weeks of initiating supraphysiologic doses, LH and FSH drop toward zero, testicular testosterone production ceases, and testicular volume decreases measurably. Sperm production, which requires intratesticular testosterone at concentrations 50 to 100 times higher than serum levels, collapses.

Duration of Suppression After High-Dose Use

A 2015 study by Liu et al. In the Journal of Clinical Endocrinology and Metabolism found that after high-dose exogenous androgen administration, full recovery of spermatogenesis took a median of 6 months, with 90% of men recovering by 24 months. [8] Men who used androgens for longer durations had proportionally longer recovery times. Rodriguez's documented use spanned at least a decade intermittently. Whether his HPG axis recovered fully between episodes is not in the public record.

Post-Cycle Hypogonadism Risk

Men who use supraphysiologic androgens without medical supervision and then abruptly stop often experience profound symptomatic hypogonadism: fatigue, depression, loss of libido, and loss of lean mass. This is sometimes called post-anabolic steroid-induced hypogonadism (ASIH). The Endocrine Society acknowledges ASIH as a recognized clinical entity requiring evaluation and, in some cases, treatment with clomiphene citrate or hCG to restore the HPG axis. [1] A non-celebrity patient who develops ASIH after recreational androgen use and presents to a physician is, paradoxically, in a clinically similar position to a post-doping athlete.

Why the Biogenesis Case Matters for Telehealth TRT Patients

The Rodriguez case receives disproportionate public attention, but it has real downstream effects on how patients and prescribers think about testosterone therapy.

The Conflation Problem

When high-profile doping cases dominate coverage of testosterone, patients seeking legitimate treatment for confirmed hypogonadism face unnecessary stigma. A 2016 analysis in JAMA Internal Medicine found that testosterone prescriptions in the United States peaked at 2.3 million per year around 2013, coinciding with aggressive direct-to-consumer marketing, and then declined sharply after FDA safety communications. [9] The doping narrative and the therapeutic narrative became inseparable in public discourse, to the detriment of men with actual symptomatic low testosterone.

What Clinicians Actually Screen For

A legitimate TRT intake includes two morning serum total testosterone measurements below 300 ng/dL, a full symptom history using a validated instrument such as the Androgen Deficiency in Aging Males (ADAM) questionnaire, a DRE or PSA for men over 40, CBC, and a metabolic panel. No credible telehealth or in-person provider issues testosterone without these baselines. The substances Rodriguez reportedly received required none of these gatekeeping steps.

The Telehealth Distinction

Telehealth TRT platforms prescribe within the same FDA-approved formulary as in-person endocrinologists. The delivery model differs; the pharmacology does not. A man prescribed testosterone cypionate 150 mg IM weekly by a telemedicine provider, monitored with quarterly labs, is receiving guideline-concordant care. The compound, the dose target, and the monitoring schedule align with Endocrine Society recommendations regardless of whether the prescribing visit happened in person or over video.

Long-Term Outcomes in Supervised vs. Unsupervised Testosterone Use

The outcomes literature almost exclusively covers supervised, guideline-dosed therapy. Extrapolating those data to supraphysiologic, polypharmacy-era doping is not scientifically valid.

Quality-of-Life Data

A 2019 systematic review in the Annals of Internal Medicine (31 trials, N=5,464) found that testosterone therapy produced small-to-moderate improvements in sexual function and moderate improvements in physical performance in hypogonadal men, with benefits most consistent in men with baseline total testosterone below 230 ng/dL. [10] Men with borderline testosterone (230 to 350 ng/dL) showed more variable benefit. These effect sizes, while real, are far smaller than the performance gains documented in elite athletes using supraphysiologic regimens.

Mortality and Cancer Data

Long-term mortality data on supervised TRT remain limited, but no trial to date has shown increased all-cause mortality. Prostate cancer risk has been a persistent concern. The current Endocrine Society position holds that testosterone therapy is contraindicated in men with untreated prostate cancer and requires careful monitoring in men with a history of treated prostate cancer. [1] For the average non-celebrity patient, the practical takeaway is routine PSA monitoring, not avoidance of therapy.

Applying the Rodriguez Case to Clinical Practice

The Rodriguez story is, in clinical terms, a cautionary PED case study wrapped in a celebrity narrative. The practical lessons for prescribers and patients are specific.

For Patients

Men considering TRT should insist on a confirmed diagnosis before starting therapy. Two morning total testosterone measurements below 300 ng/dL, combined with symptoms, meet the Endocrine Society threshold. The benefits they can realistically expect, based on TRAVERSE and the TTrials, are modest improvements in lean mass, sexual function, mood, and bone density over 12 to 24 months. These are not the performance changes Rodriguez was reportedly seeking.

For Prescribers

Any patient presenting with a history of prior androgen use, recreational or competitive, should have HPG axis recovery assessed before initiating TRT. If LH and FSH remain suppressed with low testosterone more than 6 months after stopping exogenous androgens, a diagnosis of ASIH is appropriate and clomiphene citrate 25 to 50 mg daily or hCG 1,500 to 3,000 IU three times weekly are evidence-supported first-line options to stimulate endogenous production before committing to lifelong exogenous replacement. [1]